Medlab Clinical Ltd is a renowned company that upholds its core values and corporate philosophy with utmost dedication. The company firmly believes in promoting innovative and evidence-based medical research to improve patient outcomes. With a focus on scientifically driven products, Medlab Clinical Ltd strives to develop and deliver advanced therapeutic solutions in the field of medical science. The company values integrity, commitment, and excellence, as it strives to provide cutting-edge diagnostics and personalized medicine. Medlab Clinical Ltd's dedication to upholding these values has made it a trusted name in the healthcare industry, offering high-quality solutions for better patient care.

Medlab Clinical Ltd is primarily present in Australia and New Zealand.

Some significant milestones achieved by Medlab Clinical Ltd include the successful completion of a Phase 2 trial for their lead drug candidate, NRGBiotic, for managing depression symptoms. The company has also received various regulatory approvals and successfully launched several products, including Nanabis, a cannabis-based product for pain management. Medlab Clinical Ltd has established collaborations with prestigious research institutions and universities worldwide, contributing to advancements in medical research. The company continues to expand its global reach, with strategic partnerships and acquisitions, positioning itself as an innovative leader in the field of personalized medicine and nutraceuticals.

Medlab Clinical Ltd is an Australian biotechnology company specializing in developing and commercializing novel therapeutic products for chronic diseases. Established in 2012, Medlab Clinical has rapidly emerged as a leader in the medical research and development sector. With a strong focus on scientific innovation, the company aims to improve patient outcomes through its advanced drug delivery systems and targeted treatments. Medlab Clinical has garnered recognition for its cutting-edge medical advancements, including patented NanoCelle™ technology. With a commitment to research excellence and a dedicated team of experts, Medlab Clinical continues to revolutionize the field of biotechnology and pave the way for groundbreaking medical solutions.

The main competitors of Medlab Clinical Ltd in the market include companies such as Sonic Healthcare Limited, Healius Limited, Integral Diagnostics Limited, and Capitol Health Limited. These companies also operate in the medical diagnostics and healthcare industry, offering similar services and solutions. Despite facing competition, Medlab Clinical Ltd has established a strong presence and reputation through its innovative offerings, research collaborations, and dedication to improving patient outcomes.

Medlab Clinical Ltd is primarily active in the healthcare and biotechnology industries.

The business model of Medlab Clinical Ltd is focused on innovative medical research and the development of therapeutic formulations. As a leading Australian biotech company, Medlab Clinical specializes in developing and commercializing nutraceuticals, pharmaceuticals, and diagnostic tools to improve patient outcomes. Medlab Clinical aims to leverage its expertise in advanced delivery platforms and nutraceutical products to address various health conditions, including pain management, depression, and chronic diseases. By prioritizing research-backed solutions and strategic collaborations, Medlab Clinical aims to transform healthcare through evidence-based treatments and personalized medicine.

De Medlab Clinical K/W is -0,69.

De Medlab Clinical KUV is 3,44.

De AlleAktien Kwaliteitsscore voor Medlab Clinical is 2/10.

De verwachte Medlab Clinical omzet is 4,38 mln. AUD.

De verwachte Medlab Clinical winst is -21,74 mln. AUD.

Medlab Clinical Ltd is an Australian company specializing in the development and provision of clinical diagnostic solutions for medical professionals. The company operates in three main divisions: diagnostic services, biotechnology, and research and development. The diagnostic services provide a variety of laboratory tests for medical conditions, including hormone tests, immune tests, and microbiology tests. The biotechnology division focuses on developing groundbreaking drugs and therapies for serious diseases such as inflammation and cancer. The research and development division invests in innovative technologies and products to meet the needs of medical professionals and their patients. Medlab Clinical offers a wide range of products and services, including probiotics for digestive and gut health, skin-friendly nutraceuticals, and blood tests for various medical conditions. The company's strong business model is based on innovation, research, and customer service. It aims to maintain its reputation as a leading provider of clinical diagnostic solutions and biotechnological developments through continuous innovation and excellent customer satisfaction.

Medlab Clinical keert een dividend van 0 AUD uit, verdeeld over betalingen per jaar.

De dividend kan momenteel niet worden berekend voor Medlab Clinical of het bedrijf keert geen dividend uit.

De ISIN van Medlab Clinical is AU000000MDC8.

Het WKN van Medlab Clinical is A14R7W.

De ticker van Medlab Clinical is MDC.AX.

Binnen de laatste 12 maanden betaalde Medlab Clinical een dividend van . Dit komt overeen met een dividendrendement van ongeveer . Voor de komende 12 maanden zal Medlab Clinical naar verwachting een dividend van 0 AUD betalen.

De dividendrendement van Medlab Clinical is momenteel .

Medlab Clinical betaalt elk kwartaal een dividend uit. Dit wordt uitgekeerd in de maanden .

Medlab Clinical betaalde de afgelopen 0 jaar elk jaar dividend.

Voor de komende 12 maanden wordt een dividend van 0 AUD verwacht. Dit komt overeen met een dividendrendement van 0 %.

Medlab Clinical wordt toegewezen aan de sector 'Gezondheid'.

Om het laatste dividend van Medlab Clinical van 9-9-2024 ter hoogte van 0 AUD te ontvangen, moest je het aandeel voor de ex-datum op 9-9-2024 in je portefeuille hebben.

De laatste dividenduitkering vond plaats op 9-9-2024.

In het jaar 2023 heeft Medlab Clinical 0 AUD aan dividenden uitgekeerd.

De dividenden van Medlab Clinical worden in AUD uitgekeerd.